Publika - Scientific publications from Oslo University Hospital

RSS feed RSS

Publications by Merete Bjørnslett

22 publications found

Original articles

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Bruun J, Eide PW, Bergsland CH, Bruck O, Svindland A, Arjama M, Välimäki K, Bjørnslett M, Guren MG, Kallioniemi O, Nesbakken A, Lothe RA, Pellinen T (2021)
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
Mol Oncol, 16 (12), 2312-2329
DOI 10.1002/1878-0261.13159, PubMed 34890102

Gansmo LB, Sofiyeva N, Bjørnslett M, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
Sci Rep, 11 (1), 23463
DOI 10.1038/s41598-021-02820-z, PubMed 34873230

Helwa R, Gansmo LB, Bjørnslett M, Halle MK, Werner HMJ, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
Biomarkers, 26 (4), 302-308
DOI 10.1080/1354750X.2021.1891291, PubMed 33645339

Berg KCG, Brunsell TH, Sveen A, Alagaratnam S, Bjørnslett M, Hektoen M, Brudvik KW, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA (2021)
Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases
Mol Oncol, 15 (4), 830-845
DOI 10.1002/1878-0261.12885, PubMed 33325154

Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
ESMO Open, 5 (6), e001040
DOI 10.1136/esmoopen-2020-001040, PubMed 33219056

Lopes N, Bergsland C, Bruun J, Bjørnslett M, Vieira AF, Mesquita P, Pinto R, Gomes R, Cavadas B, Bennett E, Pereira L, Lothe RA, Almeida R, David L (2020)
A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis
Gastric Cancer, 23 (5), 811-823
DOI 10.1007/s10120-020-01064-6, PubMed 32215766

Lopes N, Bergsland CH, Bjørnslett M, Pellinen T, Svindland A, Nesbakken A, Almeida R, Lothe RA, David L, Bruun J (2019)
Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2
Lab Invest, 100 (1), 120-134
DOI 10.1038/s41374-019-0336-4, PubMed 31641225

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712

Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Mol Cancer, 16 (1), 116
DOI 10.1186/s12943-017-0691-y, PubMed 28683746

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
DOI 10.1007/s13277-016-4940-2, PubMed 26867771

Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
DOI 10.1007/s10689-015-9811-2, PubMed 25980896

Bjørnslett M, Knappskog S, Lønning PE, Dørum A (2012)
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
DOI 10.1186/1471-2407-12-454, PubMed 23039163

Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
DOI 10.1371/journal.pone.0036263, PubMed 22558411

Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605

Danielsen SA, Lind GE, Bjørnslett M, Meling GI, Rognum TO, Heim S, Lothe RA (2008)
Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation- status
Hum Mutat, 29 (11), E252-62
DOI 10.1002/humu.20860, PubMed 18781614

Rustad CF, Bjørnslett M, Heimdal KR, Mæhle L, Apold J, Møller P (2006)
Germline PTEN mutations are rare and highly penetrant
Hered Cancer Clin Pract, 4 (4), 177-85
DOI 10.1186/1897-4287-4-4-177, PubMed 20223021

Aamot HV, Bjørnslett M, Delabie J, Heim S (2005)
t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations
Br J Haematol, 130 (6), 845-51
DOI 10.1111/j.1365-2141.2005.05688.x, PubMed 16156854

Axelsson L, Katla T, Bjørnslett M, Eijsink VG, Holck A (1998)
A system for heterologous expression of bacteriocins in Lactobacillus sake
FEMS Microbiol Lett, 168 (1), 137-43
DOI 10.1111/j.1574-6968.1998.tb13266.x, PubMed 9812374

Theses

Bjørnslett M (1995)
Heterologous expression of bacteriocins from lactic acid bacteria: production of skacin P from Lactobacillus sake Lb674, with the transport system of sakacin A from Lactobacillus sake Lb706
[M. Bjørnslett], Tromsø, 1 b. (flere pag.)
BIBSYS 96096715x

0.12s